These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 22372867)

  • 1. Use of radiolabeled compounds in drug metabolism and pharmacokinetic studies.
    Isin EM; Elmore CS; Nilsson GN; Thompson RA; Weidolf L
    Chem Res Toxicol; 2012 Mar; 25(3):532-42. PubMed ID: 22372867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
    Penner N; Xu L; Prakash C
    Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?
    Nassar AE; Talaat RE; Kamel AM
    Curr Opin Drug Discov Devel; 2006 Jan; 9(1):61-74. PubMed ID: 16445118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of radioactive compounds and autoradiography to determine drug tissue distribution.
    Solon EG
    Chem Res Toxicol; 2012 Mar; 25(3):543-55. PubMed ID: 22280496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HPLC/ICP-MS in combination with "reverse" online isotope dilution in drug metabolism studies.
    Meermann B; Hulstaert A; Laenen A; Van Looveren C; Vliegen M; Cuyckens F; Vanhaecke F
    Anal Chem; 2012 Mar; 84(5):2395-401. PubMed ID: 22304524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel strategies for microdose studies using non-radiolabeled compounds.
    Maeda K; Sugiyama Y
    Adv Drug Deliv Rev; 2011 Jun; 63(7):532-8. PubMed ID: 21345359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered disposition of drugs in acute renal failure rat models: drug development strategies and perspectives.
    Srinivas NR
    Arzneimittelforschung; 2010; 60(12):731-48. PubMed ID: 21265465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical and pharmacological animal models used in drug metabolism and pharmacokinetics.
    Landskroner KA; Hess P; Treiber A
    Xenobiotica; 2011 Aug; 41(8):687-700. PubMed ID: 21486193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical strategies for identifying drug metabolites.
    Prakash C; Shaffer CL; Nedderman A
    Mass Spectrom Rev; 2007; 26(3):340-69. PubMed ID: 17405144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New horizons in drug metabolism, pharmacokinetics and drug discovery.
    Palmer AM
    Drug News Perspect; 2003; 16(1):57-62. PubMed ID: 12682673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?
    Obach RS; Nedderman AN; Smith DA
    Xenobiotica; 2012 Jan; 42(1):46-56. PubMed ID: 21992031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of bioanalysis of multiple analytes in drug discovery and development: review of select case studies including assay development considerations.
    Srinivas NR
    Biomed Chromatogr; 2006 May; 20(5):383-414. PubMed ID: 16307470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Database Extraction of Metabolite Information of Drug Candidates: Analysis of 27 AstraZeneca Compounds with Human Absorption, Distribution, Metabolism, and Excretion Data.
    Iegre J; Hayes MA; Thompson RA; Weidolf L; Isin EM
    Drug Metab Dispos; 2016 May; 44(5):732-40. PubMed ID: 26868617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
    Meanwell NA
    Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo rat PK profiling in drug discovery: new challenges.
    Zonzini L; Bianchi F; Cesari N; Sartori M
    Expert Opin Drug Discov; 2010 Nov; 5(11):1031-7. PubMed ID: 22827743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.
    Mutlib A; Espina R; Atherton J; Wang J; Talaat R; Scatina J; Chandrasekaran A
    Chem Res Toxicol; 2012 Mar; 25(3):572-83. PubMed ID: 22292524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.